Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.41 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27957536 | 0.87 | GAA (0.33) | METAP2PKMMAPK1MAP2K4MAPKAPK3 | |
| SCHEMBL7855617 | 0.85 | MAPT (0.39) | METAP2PKMKIF11KDM4EMAPK1 | |
| SCHEMBL7855336 | 0.85 | METAP2 (0.49) | METAP2KIF11KDM4ENPBWR1BACE1 | |
| SCHEMBL762335 | 0.81 | KIF11 (0.41) | METAP2PKMKIF11CHUK | |
| SCHEMBL5720456 | 0.81 | TSHR (0.38) | — | |
| SCHEMBL23069661 | 0.79 | CYP3A4 (0.30) | — | |
| SCHEMBL10444103 | 0.78 | FFAR1 (0.46) | NPBWR1 | |
| SCHEMBL1843189 | 0.75 | PARP1 (0.58) | PKMKIF11KDM4EMAPK1MAP2K4 | |
| SCHEMBL6090810 | 0.75 | LCK (0.39) | — | |
| SCHEMBL1023455 | 0.75 | NPC1 (0.38) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122041642-A | Sewage treatment method based on cyclopentane heat exchange | 广东石油化工学院 | 2026-05-15 | — | — | CN | claimed |
| US-12550694-B2 | Selective deposition for integrated circuit interconnect structures | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2026-02-10 | — | — | US | claimed |
| US-12278143-B2 | Method of providing a workpiece including low resistance interconnect low-resistance interconnect | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2025-04-15 | — | — | US | claimed |
| US-20240258166-A1 | SELECTIVE DEPOSITION FOR INTEGRATED CIRCUIT INTERCONNECT STRUCTURES | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2024-08-01 | — | — | US | claimed |
| CN-117285985-A | Low-dynamic surface tension insulating layer buffer cleaning liquid and preparation method and application thereof | 四川格林达电子材料有限公司 | 2023-12-26 | — | — | CN | claimed |
| US-20230369114-A1 | Low-Resistance Interconnect | TAIWAN SEMICONDUCTOR MANUFACTORING CO., LTD (TW) | 2023-11-16 | — | — | US | claimed |
| US-20220277996-A1 | SELECTIVE DEPOSITION FOR INTEGRATED CIRCUIT INTERCONNECT STRUCTURES | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2022-09-01 | — | — | US | claimed |
| EP-0851282-B1 | Processing of a light-sensitive silver halide photographic material | AGFA GEVAERT (BE) | 2003-04-16 | — | — | EP | claimed |
| US-5912108-A | FORMING IMAGES BY EXPOSURE TO LIGHT ON SUPPORTS | AGFA-GEVAERT, N.V. (BE) | 1999-06-15 | — | — | US | claimed |
| EP-0851282-A1 | Processing of a light-sensitive silver halide photographic material | AGFA-GEVAERT N.V. (BE) | 1998-07-01 | — | — | EP | claimed |
| CN-122041642-A | Sewage treatment method based on cyclopentane heat exchange | 广东石油化工学院 | 2026-05-15 | — | — | CN | disclosed |
| US-12550694-B2 | Selective deposition for integrated circuit interconnect structures | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2026-02-10 | — | — | US | disclosed |
| US-20260033305-A1 | LOW-RESISTANCE INTERCONNECT | TAIWAN SEMICONDUCTOR MFG CO LTD (TW) | 2026-01-29 | — | — | US | disclosed |
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| US-12482743-B2 | Interconnect structure and method for forming the same | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2025-11-25 | — | — | US | disclosed |
| EP-0688217-A1 | HETEROCYCLE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994021258-A1 | HETEROCYCLE-CONTAINING MACROCYCLIC IMMUNOMODULATORS | ABBOTT LABORATORIES (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0617320-A2 | Tabular grain emulsions containing antifoggants and stabilizers | EASTMAN KODAK COMPANY (US) | 1994-09-28 | — | — | EP | disclosed |
| US-5320938-A | Occurs in the presence of iodide | EASTMAN KODAK COMPANY (US) | 1994-06-14 | — | — | US | disclosed |
| US-4871653-A | DEVELOPING IN PRESENCE OF MERCAPTO POLYAZAINDENE PROMOTERS AND NUCLEATING QUATERNARY OR HYDRAZIDE-TYPE COMPOUNDS | FUJI PHOTO FILM CO., LTD. (JP) | 1989-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12550694-B2 | Selective deposition for integrated circuit interconnect structures | CAPRIN1, PIEZO1, GJB2 | METAP2 4008/4885PKM 3966/4885KIF11 1260/4885 |
| US-20260033305-A1 | LOW-RESISTANCE INTERCONNECT | CAPZB, CTCF, PIEZO1 | METAP2 3301/4885PKM 3719/4885KIF11 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.